Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)

Abbott RealTime IDH1 and IDH2 tests (Abbott Molecular) are covered for adult patients with relapsed or refractory acute myeloid leukemia to detect IDH1 or IDH2 mutations that guide treatment with ivosidenib (TIBSOVO) or enasidenib (IDHIFA), respectively, with coverage effective 7/20/2018 (IDH1) and 8/1/2017 (IDH2). Coverage applies only to the unmodified Abbott kits; modified tests require prior MolDX Technical Assessment. Claims must use CPT 81120 (IDH1) or 81121 (IDH2) with 1 unit of service, include the appropriate DEX Z-Code in the specified claim fields, and report the appropriate ICD-10-CM diagnosis code.

"Abbott RealTime IDH1 (Abbott Molecular) is covered as an FDA-approved test to aid identification of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a susceptible ID..."

Sign up to see full coverage criteria, indications, and limitations.